Unmatched Logistics Solutions for the Life Sciences Industry

Bringing Our Extensive Experience and Compliance Expertise to Your Global Supply Chain

425
Clinical Trials
3
Commercial Products
270,000+
Shipments
100+
Countries
q3-notification 

Upcoming Events View All

DEC4

Cell Therapy Manufacturing & Gene Therapy Congress

Date: December 4 - 6, 2019
Location: Amsterdam, The Netherlands

Dec5

Cryoport Open House

Date: December 5, 2019

Location: Amsterdam, The Netherlands

The Latest From Our Blog View All

2019: The Year of Cryoport Milestones

New became the norm at Cryoport this year. The company announced new partnerships, new product lines, and new services seemingly every week. On top of these exciting developments were notable milestones in earnings and growth. Here, we share a quick recap of our biggest moments in 2019 – but please pardon us if we’re brief, as we’re busy working on what’s next.

Avoiding Catastrophe: Addressing the Supply Chain Risks in Cell and Gene Therapy Development

There is no question that the groundbreaking treatments being developed in Cell & Gene Therapy (CGT) are fundamentally changing the way patient care is managed around the world. As with most revolutionary breakthroughs in medicine or any other industry, the supply chain is critically important. These revolutionary therapies only have value if you can effectively get them to the patients, or in the case of CGT, into the patient’s vein. Furthermore, CGT treatments are extremely fragile and require weeks to develop in multiple facilities. It cannot be stressed enough that a fail-proof supply chain is necessary.